Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer
Cancer Medicine · 2023-06 · 12 (11) · 12234-12252
DOI: 10.1002/cam4.5918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 16.04.2023. Verfasst von Yue Hu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
An ever‐increasing number of efforts are focused on identifying effective biomarkers for immune checkpoint inhibitors (ICIs). Cytokines and chemokines are critical to tumor growth, metastasis, tumor angiogenesis, and the immune response against tumor cells. In the study here, we determined the correlation between circulating cytokines/chemokines and the clinical benefit of ICIs for non‐small cell lung cancer (NSCLC) patients.
Methods
Peripheral blood samples were collected before and during treatment (at 12th week). Plasma levels of cytokines/chemokines and specific stress response markers were measured using the Bio‐Plex Pro Human Cytokines Grp I Panel (27‐plex), an APEX1 detection kit, and a human LAP(TGF‐β1) immunoassay kit. A Mann–Whitney U ‐test or Wilcoxon signed‐rank test and a Cox proportional hazards model were employed for statistical analysis.
Results
In the ICI monotherapy cohort, a high level of IL‐6 at pretreatment or an elevation of IL‐6, IL‐8, FGF2, CXCL10, CCR1, PDFGB, TNF, and APEX1 posttreatment was associated with poor progress‐free survival (PFS). A posttreatment elevation (defined herein as change rate) of CXCL10 was also associated with poor overall survival (OS). In the combinational therapy group, a high level of IL‐12, IL‐17A, FGF2, VEGF, and APEX1 at pretreatment and an elevation of CCL2 posttreatment were associated with poor PFS. A high level of IL‐9, FGF2, PDFGB, CCL4, TFGB, and APEX1 at pretreatment and an elevation of IL‐13, CSF2, and CCL2 at posttreatment were associated with poor OS of patients receiving combination therapy.
Conclusions
The study here suggests that circulating cytokines/chemokines are feasible, noninvasive biomarkers for predicting clinical benefit of ICI treatment for NSCLC. Distinct circulating factor profiles were observed in individuals receiving ICI monotherapy or combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
ORCID-Profile: Yue Hu, Yanli Xiong
Zitieren
APA
Hu, Y., Li, S., Xiao, H., Xiong, Y., Lu, X., Yang, X., Luo, W., Luo, J., Zhang, S., Cheng, Y., Zhang, L., Dai, X., Yang, Y., Wang, D., & Li, M. (2023). Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer. Cancer Medicine, 12(11), 12234-12252. https://doi.org/10.1002/cam4.5918
Vancouver
Hu Y, Li S, Xiao H, Xiong Y, Lu X, Yang X, et al. Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer. Cancer Medicine. 2023;12(11):12234-12252. doi:10.1002/cam4.5918
BibTeX
@article{Hu2023,
author = {Hu, Yue and Li, Shixun and Xiao, He and Xiong, Yanli and Lu, Xianfeng and Yang, Xiao and Luo, Wei and Luo, Jiamin and Zhang, Shiheng and Cheng, Yi and Zhang, Lei and Dai, Xiaoyan and Yang, Yuxin and Wang, Dong and Li, Mengxia},
title = {Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {11},
pages = {12234--12252},
doi = {10.1002/cam4.5918}
}
EUVIMED